Biozipcode, Inc. was established in January of Reiwa year 4th (2022) with a capital of 70 million yen. Funding has been provided by Representative Director Fumihisa Kojima and Studio Makyu Co., Ltd, along with their collaborating companies.

The development costs for new drugs usually range from several tens of million to hundred millions of USD, and funding is planned through investors, VCs, government and private grants, and partnerships for joint research.